Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 27;108(6):1640–1651. doi: 10.3324/haematol.2021.280424

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2023 Ferrata Storti Foundation

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Figure 3. — Use of immunomodulatory drugs and/or proteasome inhibitors in first-treatment line of multiple myeloma by country and age group. In 2009 the Danish treatment guidelines changed to recommending bortezomib and dexamethasone (VD) in first line for patients eligible for autologous stem cell transplant (ASCT) and melphalan, prednisolone and thalidomide (MPT) or melphalan, prednisolone and bortezomib (MPV) for those ineligible (marked by the red vertical line). In Sweden, the treatment guidelines changed in 2010 (blue vertical line). Bortezomib and thalidomide were recommended as part of standard induction treatment before ASCT. MPT was recommended as standard for patients not eligible for ASCT, while MPV and melphalan and prednisolone were treatment options.